Non-Small Cell Lung Cancer

The Non-Small Cell Lung Cancer pipeline: 587 tracked drugs, 60 approved for this indication.

60 approved / phase 4105 Phase 311 Phase 2/382 Phase 2132 Phase 1/2138 Phase 159 preclinical / unstaged

Compare the share prices of listed companies in Non-Small Cell Lung Cancer →

Total attributable cost

$12.5B

$70,896/patient

Drug spend

Not yet sourced

How this is calculated ↗

All stages, newly diagnosed (2026 incidence estimate) · US

The Non-Small Cell Lung Cancer pipeline

Key trial results for every approved and late-stage drug: Non-Small Cell Lung Cancer results by drug.

← all assets